A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
ConditionProteinuric Kidney Disease
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-68
SponsorMaze Therapeutics
About this trial
The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2
Chronic kidney disease with persistent albuminuria
Disqualifiers
Organ or bone marrow transplantation
History of active cancer within past 2 years, except for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer
Conditions that may alter drug absorption, e.g., history of bariatric surgery
Type I diabetes
Trial design
Design model
Single group
Treatments tested in this trial
MZE829
DrugCapsules for oral administration
Treatment groups
74 Participants
are divided into 1 treatment groupGroup A: MZE829Experimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Safety and tolerability as assessed by incidence of adverse events (AEs)
Time frame
Baseline to Week 12Secondary outcomes
1
Percent participants with ≥30% reduction from baseline in UACR at Week 12
Time frame
Baseline to Week 122
Geometric mean plasma drug concentrations
Time frame
Baseline to Week 12Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov